# US 2020/0286625 A1 · Biological data signatures of aging and methods of determining a biological aging clock

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0286625 A1
- Document ID: US20200286625A1
- Status: Published application
- Kind: A1
- Application number: 16/883,205
- Filed: 2020-05-26
- Published: 2020-09-10
- Earliest claimed: 2017-07-25
- Assignees: Insilico Medicine IP Limited
- Applicants: Insilico Medicine IP Limited
- Inventors: Aleksandr M. Aliper; Evgeny Olegovich Putin; Aleksandrs Zavoronkovs
- Web page: https://patentgrep.com/patent/US20200286625A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12N 15/85: for animal cells
- G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)}
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 40/20: Supervised data analysis
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

A method of creating a biological aging clock for a subject can include: (a) receiving a biological data signature derived from a tissue or organ of the subject; (b) creating input vectors based on the biological data signature; (c) inputting the input vectors into a machine learning platform; (d) generating a predicted biological aging clock of the tissue or organ based on the input vectors by the machine learning platform, wherein the biological aging clock is specific to the tissue or organ; and (e) preparing a report that includes the biological aging clock that identifies a predicted biological age of the tissue or organ. The biological data signature can be based on biological pathway activation signatures for genomics, transcriptomics, proteomics, methylomics, metabolomics, lipidomics, glycomics, or secretomics.

## Claims

### Claim 1

A method of creating a biological aging clock for a subject, the method comprising:
(a) receiving a biological data signature derived from a tissue or organ of the subject;
(b) creating input vectors based on the biological data signature;
(c) inputting the input vectors into a machine learning platform;
(d) generating a predicted biological aging clock of the tissue or organ based on the input vectors by the machine learning platform, wherein the biological aging clock is specific to the tissue or organ; and
(e) preparing a report that includes the biological aging clock that identifies a predicted biological age of the tissue or organ.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
creating at least a second biological aging clock by repeating any one or more of steps (a), (b), (c), and/or (d), wherein the second biological aging clock is based on a second biological data signature from the tissue or organ of the subject, a different tissue or organ of the subject, or a tissue or organ of a second subject; and
optionally, preparing a report that includes the second biological aging clock that identifies a second predicted biological age of the tissue or organ of the subject, a different tissue or organ of the subject, or a tissue or organ of a second subject.

### Claim 3 (depends on 2)

The method of claim 2, further comprising:
combining the biological aging cock with the second biological aging clock to create a synthetic biological aging clock, wherein the synthetic biological aging clock provides a synthetic biological age of the tissue, organ, or of the subject; and
optionally, preparing a report that includes the synthetic biological aging clock that identifies the synthetic biological age of the tissue, organ, or of the subject.

### Claim 4 (depends on 3)

The method of claim 3, further comprising one or more of:
comparing the predicted biological age of the tissue or organ with the actual age of the subject;
comparing the second predicted biological age of the tissue or organ with the actual age of the subject; or
comparing the synthetic biological age of the tissue or organ and with the actual age of the subject,
wherein the method further comprises:
preparing a report with the comparing and with a difference from the actual age of the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the report includes one or more of:
a therapeutic regimen based on the predicted biological age in view of an actual age of the subject;
a diet regimen based on the predicted biological age in view of an actual age of the subject;
a questionnaire about lifestyle habits;
a prognosis of the life expectancy with and/or without the therapeutic regimen;
a prognosis of the life expectancy with and/or without the diet regimen;
a prognosis of the probability of survival of patient during the therapeutic regimen;
a prognosis of the probability of survival of patient during the diet regimen;
a prognosis of developing disease complications or therapy side effects;
a prognosis of the severity degree of diseases including infectious diseases such severe acute respiratory syndrome, coronavirus disease 2019 and others;
an identification of disease stages including infectious diseases and others; or
a prognosis of physical fitness of the patient.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tissue or organ are:
diseased;
healthy;
determined as susceptible to disease;
undergoing senescence;
in pre-senescence; or
non-senescent.

### Claim 7 (depends on 5)

The method of claim 5, wherein the therapeutic regimen includes one or more of:
applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject;
applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject;
introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ;
carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ; or
one or more actions that prevent further senescence or degradation of the tissue or organ is derived from the computational proteome analysis of the tissue or organ of the subject.

### Claim 8 (depends on 1)

The method of claim 1, further comprising:
performing feature importance analysis for ranking genes or gene sets by their importance in age prediction by using the biological data;
correlating a genomics profile with the predicted biological age of the subject;
correlating a proteomics profile with the predicted biological age of the subject;
correlating a transcriptomics profile with the predicted biological age of the subject;
correlating a metabolomics profile with the predicted biological age of the subject;
correlating a lipidomics profile with the predicted biological age of the subject;
correlating a glycomics profile with the predicted biological age of the subject;
correlating a secretomics profile with the predicted biological age of the subject;
correlating a methylomics profile with the predicted biological age of the subject;
identifying a subset of a genes or gene sets or biological pathways thereof that are selected as targets the therapeutic regimen; or
correlating a biological signaling pathway signature with the predicted biological age of the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the biological data signature is based on biological pathway activation signatures for genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, methylomics, or secretomics.

### Claim 10 (depends on 1)

The method of claim 1, further comprising:
obtaining biological sample of the tissue or organ of the subject; and
obtaining the biological data by performing a measurement of the genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, methylomics, or secretomics.

### Claim 11 (depends on 1)

The method of claim 1, wherein the biological data signature is based on a simulation by a computer program for biological pathway activation signatures for genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, methylomics, or secretomics.

### Claim 12 (depends on 1)

The method of claim 1, wherein the biological data is an omics signature of biological data.

### Claim 13 (depends on 12)

The method of claim 12, wherein the omics signature is genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, methylomics, or secretomics.

### Claim 14 (depends on 1)

The method of claim 1, after a defined time period,
performing steps (a), (b), (c), (d), and (e) in a second iteration; and
comparing the initial report with the report of the second iteration; and
determining a change in the predicted biological age over the defined time period.

### Claim 15 (depends on 1)

The method of claim 1, further comprising:
performing a therapeutic regimen over a defined time period,
performing steps (a), (b), (c), (d), and (e) in a second iteration; and
comparing the initial report with the report of the second iteration;
determining a change in the predicted biological age over the defined time period; and
determining:
whether the therapeutic regimen changed the predicted biological age,
if the therapeutic regimen changed the predicted biological age, then determine whether or not to: continue therapeutic regimen, change therapeutic regimen, or stop therapeutic regimen, or
if the therapeutic regimen does not change the predicted biological age, then determine whether or not to: continue therapeutic regimen, change therapeutic regimen, or stop therapeutic regimen.

### Claim 16 (depends on 1)

The method of claim 1, further comprising performing one or more of:
a therapeutic regimen based on the predicted biological age in view of an actual age of the subject; or
a diet regimen based on the predicted biological age in view of an actual age of the subject.

### Claim 17 (depends on 1)

The method of claim 1, further comprising performing one or more of
an actuarial assessment of the subject based on the predicted biological age;
a risk assessment based the predicted biological age;
an insurance assessment based on the predicted biological age.

### Claim 18 (depends on 1)

The method of claim 1, further comprising:
(f) receiving a second biological data signature derived from a baseline, the second biological data signature being from a second organ or tissue of the subject or a second subject, the organ or tissue being the same or different from the second organ or tissue; and
computing a difference between the signature of (a) and the signature of (f) to provide input vectors to the machine learning platform, wherein the machine learning platform outputs classification vectors that comprise components of the biological aging clock.

### Claim 19 (depends on 14)

The method of claim 14, wherein at least one of the biological data signature is based on an in silico biological pathway activation network decomposition.

### Claim 20 (depends on 1)

The method of claim 1, further comprising creating at least a second biological aging clock by:
(a2) receiving at least two omics signatures derived from a tissue or organ of the subject, wherein the at least two omics signature is selected from genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, methylomics, or secretomics, wherein the first input vectors are based on a first omics signature;
(b2) creating second input vectors based on a second omics signature;
(c2) inputting the first and second input vectors based on the at least two omics signatures into a machine learning platform;
(d2) generating a second predicted biological aging clock of the tissue or organ based on the second input vectors by the machine learning platform, wherein the second predicted biological aging clock is specific to the tissue or organ; and
(e2) preparing the report or a second report that includes the second biological aging clock that identifies a predicted biological age of the tissue or organ.

### Claim 21 (depends on 20)

The method of claim 20, further comprising:
combining the biological aging cock with the second biological aging clock to create a synthetic biological aging clock, wherein the synthetic biological aging clock provides a synthetic biological age of the tissue, organ, or of the subject; and
optionally, preparing a report that includes the synthetic biological aging clock that identifies the synthetic biological age of the tissue, organ, or of the subject.

### Claim 22

A computer program product comprising a tangible, non-transitory computer readable medium having a computer readable program code stored thereon, the code being executable by a processor to perform a method for biological aging clock for a patient, the method comprising:
(a) receiving a biological data signature derived from a tissue or organ of the subject;
(b) creating input vectors based on the biological data signature;
(c) inputting the input vectors into a machine learning platform;
(d) generating a predicted biological aging clock of the tissue or organ based on the input vectors by the machine learning platform, wherein the biological aging clock is specific to the tissue or organ; and
(e) preparing a report that includes the biological aging clock that identifies a predicted biological age of the tissue or organ.

### Claim 23 (depends on 22)

The computer program product of claim 22, the method further comprising:
creating at least a second biological aging clock by repeating any one or more of steps (a), (b), (c), and/or (d), wherein the second biological aging clock is based on a second biological data signature from the tissue or organ of the subject, a different tissue or organ of the subject, or a tissue or organ of a second subject; and
optionally, preparing a report that includes the second biological aging clock that identifies a second predicted biological age of the tissue or organ of the subject, a different tissue or organ of the subject or a tissue or organ of a second subject.

### Claim 24 (depends on 23)

The computer program product of claim 23, the method further comprising:
combining the biological aging cock with the second biological aging clock to create a synthetic biological aging clock, wherein the synthetic biological aging clock provides a synthetic biological age of the tissue, organ, or of the subject; and
optionally, preparing a report that includes the synthetic biological aging clock that identifies the synthetic biological age of the tissue, organ, or of the subject.

### Claim 25 (depends on 24)

The computer program product of claim 24, the method further comprising:
comparing the predicted biological age of the tissue or organ with the actual age of the subject;
comparing the second predicted biological age of the tissue or organ with the actual age of the subject;
comparing the synthetic biological age of the tissue or organ and with the actual age of the subject,
wherein the method further comprises:
preparing a report with the comparing and with a difference from the actual age of the subject.

### Claim 26 (depends on 22)

The computer program product of claim 22, the method further comprising:
performing feature importance analysis for ranking genes or gene sets by their importance in age prediction by using the biological data;
correlating a genomics profile with the predicted biological age of the subject;
correlating a proteomics profile with the predicted biological age of the subject;
correlating a transcriptomics profile with the predicted biological age of the subject;
correlating a metabolomics profile with the predicted biological age of the subject;
correlating a lipidomics profile with the predicted biological age of the subject;
correlating a glycomics profile with the predicted biological age of the subject;
correlating a secretomics profile with the predicted biological age of the subject;
correlating a methylomics profile with the predicted biological age of the subject;
identifying a subset of a genes or gene sets or biological pathways thereof that are selected as targets the therapeutic regimen; or
correlating a biological signaling pathway signature with the predicted biological age of the subject.

### Claim 27 (depends on 22)

The computer program product of claim 22, the method further comprising:
after a defined time period,
performing steps (a), (b), (c), (d), and (e) in a second iteration; and
comparing the initial report with the report of the second iteration; and
determining a change in the predicted biological age over the defined time period.

### Claim 28 (depends on 22)

The computer program product of claim 22, wherein the biological data signature is based on biological pathway activation signatures for genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, or secretomics.

### Claim 29 (depends on 22)

The computer program product of claim 22, wherein the biological data signature is based on a simulation by a computer program for biological pathway activation signatures for genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, or secretomics.

### Claim 30 (depends on 22)

The computer program product of claim 22, wherein the biological data is an omics signature of biological data.

### Claim 31 (depends on 22)

The computer program product of claim 22, wherein the omics signature is genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, or secretomics.
